Market Place
Sourcing Support
Rexahn Announces Expected Effectiveness of Reverse Stock Split and Merger
05 Nov 2020 //
BIOSPACE
Rexahn and Ocuphire Enter into Definitive Merger Agreement
18 Jun 2020 //
BIO SPACE
Rexahn licenses pancreatic cancer drug candidate in China
19 Apr 2019 //
IN-PHARMATECHNOLOGIST
Rexahn & BioSense Enter License Agreement
16 Apr 2019 //
GLOBENEWIRE
BioXcel Therapeutics Enhances Leadership with Appointment of Vikas Sharma
31 Jul 2018 //
NASDAQ
Global Renal Cell Cacinoma Drugs Market Overview 2018- Rexahn Bionomics,Cerulean
29 Jul 2018 //
TRUEINDUSTRY
Pluristem, Rexahn, Are Biotech Winners, B Riley FBR Says In Bullish Initiation
15 Jul 2018 //
BENZINGA
Rexahn Ph2a Combination Study of RX-3117 and Abraxane®
15 May 2018 //
GLOBENEWSWIRE
Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
13 Mar 2018 //
PRESS RELEASE
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117
12 Feb 2018 //
PRESS RELEASE
Rexahn Collab with Zhejiang Haichang Biotech for the Dev of RX-0201 Archexin®
08 Feb 2018 //
PRESS RELEASE
Rexahn Receives Notice of Allowance for A New U.S. Patent-RX-5902 (Supinoxin™)
29 Jan 2018 //
PRESS RELEASE
Rexahn Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients
22 Jan 2018 //
PRESS RELEASE
Rexahn New Preclinical Data on Supinoxin™ at 2017 S.A Breast Cancer Symposium
11 Dec 2017 //
PRESS RELEASE
Rexahn`s Doses 1st Patient in a PhIIa CTRL RX-3117 in Combination with Abraxane®
08 Nov 2017 //
PRESS RELEASE
Rexahn Announces $8 Million Registered Direct Offering
13 Oct 2017 //
PRESS RELEASE
Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
13 Aug 2017 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.